The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
Link
![www.ncbi.nlm.nih.gov](/proxy.php?image=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fcorehtml%2Fpmc%2Fpmcgifs%2Fpmc-card-share.jpg%3F_%3D0&hash=6cdefc9dbe5938800afa77ae8aa3224d&return_error=1)
The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
Inflammation is a common pathological phenomenon of osteoarthritis (OA). Accumulated evidence indicates that ameliorating or suppressing inflammation might be a promising and effective therapeutic strategy for the treatment of OA. Notably, glucagon-like ...
![www.ncbi.nlm.nih.gov](/proxy.php?image=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fcoreutils%2Fnwds%2Fimg%2Ffavicons%2Ffavicon.png&hash=8e4cab966598f6b5c4313806c7aad248&return_error=1)